$9.72−0.21 (−2.11%)
At close: Oct 2, 2026, 4:00 PM ET
Adma Biologics Inc · Overview
Industry: Drugs · see every company filed here →
Adma Biologics Inc scores 69/100. Solid. Strongest on growth and quality, trading at 13× earnings versus 400 Healthcare peers.
Tenet Score · vs sector
n=400Solid
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value70
Quality70
Health66
Growth72
Factor grades
Grid rings: 25 · 50 · 75 · 100 percentile
ValueBQualityBHealthCGrowthBMomentumF
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Price
Loading chart…
P/E
13.2×
price ÷ trailing EPS, Oct 1, 2026 close
P/B
5.4×
cap ÷ Jun 30, 2026 book value, Oct 1, 2026 close
P/S
4.4×
price to fiscal 2025 sales
ROE
42%
TTM through Jun 30, 2026
Operating margin
37.5%
fiscal 2025, before interest and tax
Net margin
33.0%
TTM through Jun 30, 2026
Current ratio
6.97
Jun 30, 2026 balance sheet
Net debt / EBITDA
−0.1×Tenet-derived Total debt less cash and short-term investments, over EBITDA (operating income plus depreciation and amortisation) from the filed statements. Long-term investments are not counted as cash. For some companies they include marketable securities held for more than a year. Computed by Tenet from the filed statements (formula house-nde.v1), because the data vendor published no value for this year.
computed by Tenet from the filed statements
EPS CAGR 3y
—
needs five years of positive earnings
Market cap
$2.2B
mid cap
Div yield
0.00%
reinvests all
52-wk range
7.21 – 20.46
low → high
Market cap: share price × the latest quarter's diluted weighted-average share count (vendor).
The whole report, at a glance · every card is a live peek, click any to open the section
Tenets
5 / 17
- ✓ Buffett Quality
- ~ Piotroski F-Score
- ✓ Munger Compounders
- ✓ Magic Formula
- ✕ Graham Defensive
- ✕ Quality Compounder
+11 more →
Financials
Revenue, margins and the five-year statements.Analyst Forecasts
Consensus estimates are on the Analyst tab.
Earnings
Report dates and the beat-versus-miss record.Statistics
ROIC29%
Gross margin65%
Debt / equity0.50
Technical Analysis
Mixed short-term signalvs 50-day+5.9%
vs 200-day−15.8%
RSI (14)58
News & Insights
Headlines are on the News tab.Dividends
0.00% yield
Pays no dividend. Every dollar of profit is reinvested into the business.
Ownership
94% institutional
13F flows & insider trades land here.
About Adma Biologics Inc
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BI…
Composite computed 2026-10-02 · peer basis: Healthcare (n=400) · every glimpse links to its full section with sources · not investment advice.
ETF exposure
Free account: the funds that hold ADMA, and at what weight. Everything else on this page stays open.Create a free account